Page last updated: 2024-10-27

berotek and Carcinoma, Bronchogenic

berotek has been researched along with Carcinoma, Bronchogenic in 1 studies

Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.

Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Congleton, J1
Muers, MF1

Trials

1 trial available for berotek and Carcinoma, Bronchogenic

ArticleYear
The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy.
    Respiratory medicine, 1995, Volume: 89, Issue:4

    Topics: Adult; Aged; Airway Obstruction; Albuterol; Bronchodilator Agents; Carcinoma, Bronchogenic; Drug Com

1995